PF-06650833 + ritlecitinib

PF-06650833 + ritlecitinib is an investigational **oral combination therapy** developed for the treatment of immune-mediated diseases, specifically rheumatoid arthritis. PF-06650833 is a potent, selective small molecule inhibitor of **interleukin-1 receptor-associated kinase 4 (IRAK4)**, and ritlecitinib (code name PF-06651600) is an oral **Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (TEC family kinase)** inhibitor. This combination targets distinct and non-overlapping inflammatory signaling pathways, offering a potentially synergistic effect on reducing inflammation in conditions such as rheumatoid arthritis. Early phase studies and clinical trials have demonstrated that both agents, individually and together, reduce markers of disease activity and inflammation and are generally well tolerated in combination. The combination has been primarily studied in adults with moderate to severe rheumatoid arthritis who have had an inadequate response to methotrexate[1][3][4].